These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 25473151)

  • 41. Treating hepatitis C infection by targeting the host.
    Salloum S; Tai AW
    Transl Res; 2012 Jun; 159(6):421-9. PubMed ID: 22633094
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
    Tanimine N; Tanaka Y; Abe T; Piao J; Chayama K; Ohdan H
    Transplantation; 2016 Feb; 100(2):355-64. PubMed ID: 26714120
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.
    Fauvelle C; Colpitts CC; Keck ZY; Pierce BG; Foung SK; Baumert TF
    Expert Rev Vaccines; 2016 Dec; 15(12):1535-1544. PubMed ID: 27267297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies.
    Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA
    J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The interaction between HCV and nuclear receptor-mediated pathways.
    Raglow Z; Thoma-Perry C; Gilroy R; Wan YJ
    Pharmacol Ther; 2011 Oct; 132(1):30-8. PubMed ID: 21620888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.
    Dent M; Hamorsky K; Vausselin T; Dubuisson J; Miyata Y; Morikawa Y; Matoba N
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):185-198. PubMed ID: 32861832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [HCV entry as a new therapeutic target in chronic hepatitis C].
    Dabrowska MM; Panasiuk A; Flisiak R
    Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
    Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
    Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents.
    Suraweera D; Saab EG; Tong MJ; Saab S
    Exp Clin Transplant; 2016 Jun; 14(3):243-51. PubMed ID: 27221717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".
    Gane EJ; Agarwal K
    Am J Transplant; 2014 May; 14(5):994-1002. PubMed ID: 24730431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy.
    Querenghi F; Yu Q; Billaud G; Maertens G; Trépo C; Zoulim F
    J Viral Hepat; 2001 Mar; 8(2):120-31. PubMed ID: 11264732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.
    Coppola N; Pisaturo M; Zampino R; Macera M; Sagnelli C; Sagnelli E
    World J Gastroenterol; 2015 Oct; 21(38):10749-59. PubMed ID: 26478667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
    Prentoe J; Bukh J
    Front Immunol; 2018; 9():2146. PubMed ID: 30319614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial.
    Jiménez-Luévano MÁ; Lerma-Díaz JM; Hernández-Flores G; Jiménez-Partida MÁ; Bravo-Cuellar A
    Ann Hepatol; 2013; 12(2):248-55. PubMed ID: 23396736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    Bukh J
    J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of chronic hepatitis C in Asia: when East meets West.
    Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.
    Amador-Cañizares Y; Martínez-Donato G; Alvarez-Lajonchere L; Vasallo C; Dausá M; Aguilar-Noriega D; Valenzuela C; Raíces I; Dubuisson J; Wychowski C; Cinza-Estévez Z; Castellanos M; Núñez M; Armas A; González Y; Revé I; Guerra I; Pérez Aguiar A; Dueñas-Carrera S
    World J Gastroenterol; 2014 Jan; 20(1):148-62. PubMed ID: 24415868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.